According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

Brandy Was a Hit Drink. Now It's a Poster Child for the Trade Wars. The preferred quaff of aristocrats and rappers is a key export for European luxury-drink makers, which are fighting tariff assaults ...

ASX health stocks jumped 1.6% over five days, with wound management house Tetratherix making its ASX debut, breaking the IPO ...

Neurizon enters global licensing agreement with ElancoNeurizon Therapeutics (ASX:NUZ) has signed an exclusive global ...